Novo Nordisk
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
August 22, 2025Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
August 19, 2025Mergers and Acquisitions, Research and Development BioMed X, Novo Nordisk, Pharmacy, drug development, therapeutic peptides
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of therapeutic peptides – a major …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Novo Nordisk presents promising findings for haemophilia treatment
June 23, 2025Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Novo Nordisk Foundation expands ambitious Challenge Programme internationallyÂ
April 30, 2025Research and Development Challenge Programme, Denmark, Novo Nordisk, Pharmacy, international
The Novo Nordisk Foundation Challenge Programme, a leading open competition grant programme, invites researchers outside of Denmark to participate and …
Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial
April 1, 2025Research and Development Cardiology, Novo Nordisk, cardiometabolic diseases, research and development
Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
March 22, 2024Medical Communications CHMP, Diabetes, Novo Nordisk, diabetes
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
February 23, 2024Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
January 10, 2024Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …
Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark
November 10, 2023Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …
Novo Nordisk partners with UNICEF to prevent global childhood obesity
September 21, 2023Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Novo Nordisk acquires Embark Biotech and its lead metabolic programme
August 31, 2023Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …
